The U.S. government is progressing towards loosening its regulations on marijuana, with the Justice Department preparing to adjust its classification. An executive order from December 18 under President Trump is expected to move marijuana from its current “Schedule 1” status—reserved for the most dangerous drugs—into a less restrictive category, likely “Schedule 3,” which includes certain prescription medications such as codeine-laced Tylenol.
This potential change, driven by U.S. Attorney General Pam Bondi, may unlock increased investment opportunities for the cannabis industry, valued at approximately $70 billion. Stakeholders in the industry are hopeful that this reclassification will facilitate greater financial support, as conventional banks currently avoid lending to cannabis businesses due to the existing federal restrictions.
Sources close to the situation indicate that while there is no official deadline for the announcement, the process is ongoing and discussions are taking place within the department. However, skepticism remains about the full acceptance of marijuana, particularly with concerns regarding its use among minors and the administration’s overall stance.
Optimism persists among investors, with some believing that the administration’s moves signal a shift in the regulatory landscape, spurred by political factors ahead of the midterm elections. Hedge funds are noticing refinancing activities within major cannabis companies, fueling confidence in the potential for future growth despite the prevailing uncertainty in Washington.
Why this story matters
Key takeaway
Opposing viewpoint
